J
Jerald P. Radich
Researcher at Newcastle University
Publications - 6
Citations - 373
Jerald P. Radich is an academic researcher from Newcastle University. The author has contributed to research in topics: Myeloid leukemia & Imatinib mesylate. The author has an hindex of 1, co-authored 6 publications receiving 372 citations.
Papers
More filters
Journal ArticleDOI
Chronic Myelogenous Leukemia
TL;DR: Through rational drug development, STI571, a bcr-abl tyrosine kinase inhibitor, has emerged as targeted therapy that offers new hope for expanded treatment options for patients with CML.
Feasibility of Peripheral Blood Sampling and Correlation Between Early and Late Responses in Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase: Post-Hoc Analyses of Molecular Monitoring of Imatinib Response in the RIGHT Study
Luke P. Akard,Jorge Cortes,Maher Albitar,Stuart L. Goldberg,Ghulam Warsi,Meir Wetzler,Solveig G. Ericson,Jerald P. Radich +7 more
TL;DR: This research presents a novel and scalable approach called “cell reprograming” that allows for real-time, 3D image analysis of the immune response to chemotherapy-like symptoms in mice.
accelerated-phase chronic myelogenous leukemia inhibitor, is active in patients with imatinib-resistant or -intolerant Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase
Yaping Shou,Hagop M. Kantarjian,Yok-Lam Kwong,Michele Baccarani,Timothy Hughes,Giovanni Martinelli,Jerald P. Radich,Andreas Hochhaus,Francois-Xavier Mahon,Giuseppe Saglio,Marco Gobbi,Jane F. Apperley,Richard A. Larson,E Abruzzese,Stephen G. O'Brien,Oliver G. Ottmann,Francis J. Giles,Dong-Wook Kim,Jorge Cortes +18 more
mutations and for expressing results transcripts and kinase domain BCR-ABL methodology for detecting inhibitors - Review and recommendations for 'harmonizing' current Monitoring CML patients responding to treatment with tyrosine kinase
Giuseppe Saglio,Simona Soverini,John M Goldman Grimwade,Rüdiger Hehlmann,Suzanne Kamel-Reid,Jeffrey H. Lipton,Janina A. Longtine,Michele Baccarani,Jorge Cortes,Brian J. Druker,Jean Gabert,P Hughes,Michael W. Deininger,Andreas Hochhaus,Susan Branford,Jerald P. Radich +15 more
TL;DR: The results of a consensus meeting that took place at the NIH in Bethesda in October 2005 are summarized and suggestions for harmonizing the differing methodologies for measuring BCR-ABL transcripts in CML patients undergoing treatment are made.
Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop. - eScholarship
Richard A. Van Etten,Michael J. Mauro,Jerald P. Radich,John M. Goldman,Giuseppe Saglio,Catriona Jamieson,Simona Soverini,Carlo Gambacorti-Passerini,Rüdiger Hehlmann,Giovanni Martinelli,Danilo Perrotti,David T. Scadden,Tomasz Skorski,Ayalew Tefferi,Tariq I Mughal +14 more
TL;DR: This report summarizes the most recent advances in the biology and therapy of CML that were presented at the ASH meeting and discussed at the Post-ASH International Workshop on Chronic Myeloid Leukemia and Myeloproliferative Neoplasms.